Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)
Abroad (travel likely)RecruitingPHASE2
Conditions
Active Surveillance · Clear Cell Renal Cell Carcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
MD Anderson Cancer Center, Houston, Texas, United States
Contact: Principal Investigator (Eric Jonasch, MD)
Study leads
Eric Jonasch, MD
Principal Investigator
M.D. Anderson Cancer Center